{"url_path":"/sec/apm/8-k/2026-07-20/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","accession_number":"0001213900-26-079416","cik":"0001734005","ticker":"APM","issuer_name":"Niki BioSolutions, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","primary_entity_key":"0001734005","primary_entity_name":"Niki BioSolutions, Inc."},"word_count":853,"has_tables":true,"body_markdown":"**Item 2.01. Completion of Acquisition or Disposition\nof Assets.**\n\n \n\nOn July 20, 2026 (the “Closing Date”),\nafter obtaining the requisite shareholder approval and satisfying the closing conditions, Aptorum consummated its previously announced\nmerger (the “Closing”) pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”),\nbetween Aptorum and DiamiR Biosciences Corp., a Delaware corporation (“DiamiR”), pursuant to which, among other matters, Aptorum\nwas to form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”).\n\n \n\nPursuant to the terms of the Merger Agreement and as described in the sections\ntitled “*Prospectus Summary*” and “*The Domestication Proposal*” of the Proxy Statement/Prospectus,\nimmediately prior to the Closing on July 20, 2026, Aptorum affected a domestication under Section 388 of the General Corporation Law of\nthe State of Delaware (the “DGCL”) and Section 206 of the Companies Act (as revised) of the Cayman Islands (the “Domestication”),\npursuant to which Aptorum transferred by way of continuation to and became a Delaware corporation. On July 20, 2026, immediately following\nthe Domestication, Merger Sub merged with and into DiamiR in accordance with the applicable provisions of the DGCL, with DiamiR continuing\nas the surviving company and a wholly-owned subsidiary of Aptorum (the “Merger”). As part of the Domestication, Aptorum changed\nits name to Niki BioSolutions, Inc. (the “Company” or “Niki”) and filed Niki’s Certificate of Incorporation\nwith the Delaware Secretary of State, which replaced Aptorum’s memorandum and articles in effect as of such time. In connection\nwith the Merger, the Company’s common stock, par value $0.0001 per share (the “Niki Common Stock”), trades on Nasdaq\nunder the symbol “NIKI”. In connection with the name change, the CUSIP number for the Niki Common Stock is *653942 102*.\n\n \n\nFollowing the Domestication, each then issued and outstanding Class A\nordinary share of Aptorum converted automatically, on a one-for-one basis, into a share of Niki’s common stock, par value $0.0001\nper share (the “Niki Common Stock”), and each then issued and outstanding Class B ordinary share of Aptorum converted\nautomatically into a share of Niki Common Stock and a share of Niki’s non-voting and non-convertible Series A preferred\nstock (the “Series A Preferred Stock”). Accordingly, a total of 814,375 shares of Niki Common Stock and 179,693 shares\nof Series A Preferred Stock, respectively, were issued to Aptorum’s existing shareholders.\n\n \n\nPursuant to the Merger, each then-outstanding share of DiamiR’s\ncommon stock were converted into a number of shares of Niki Common Stock equal to the Conversion Ratio, which was the number resulting\nfrom dividing (i) 0.4102, which is the quotient of dividing the total number of Aptorum ordinary shares on a fully diluted basis by the\ntotal number of shares of DiamiR common stock on a fully diluted basis, by (ii) three-seventh (3/7). Accordingly, a total of 1,979,216 shares\nof Niki Common Stock were issued to current stockholders of DiamiR; no shares of Series A Preferred Stock was issued to any current DiamiR\nstockholders.\n\n \n\nPursuant to the terms of the Merger Agreement\nand as described in the section titled “*The SIP*” of the Proxy Statement/Prospectus, Niki also adopted, as approved\nby the requisite shareholder votes, the 2026 Incentive Plan (referred to as the 2025 Incentive Plan in the Proxy Statement/Prospectus).\n\n \n\nConcurrently with the execution of the Merger Agreement, DiamiR and Aptorum\nTherapeutics Limited, a wholly owned subsidiary of Aptorum (“Aptorum Therapeutics”), entered into a management services agreement\n(as amended, the “Management Services Agreement”), which terminated as of the closing of the transaction contemplated by the\nMerger Agreement. In addition, concurrently with the execution of the Merger Agreement, DiamiR, DiamiR, LLC, a wholly owned subsidiary\nof DiamiR, Aptorum and Aptorum Therapeutics entered into an intellectual property license agreement (“Licensing Agreement”),\npursuant to which DiamiR and DiamiR, LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics\nin exchange for upfront and periodic payments and royalties until the earlier of the closing of the Merger or July 31, 2026, and therefore\nit terminated as of the Closing. The parties also entered into a Voting and Support Agreement, as well as a Stockholder Agreement (collectively\nwith the Management Services Agreement and Licensing Agreement, the “Transaction Documents”), pursuant to which certain parties\nagreed to vote in favor of certain corporate actions. The final form of Stockholder Agreement is filed as Exhibit 10.4 hereto; it includes\na reduction in the ownership percentage required to be a signatory thereto after further negotiations between the parties. Reference is\nmade to the section of the Proxy Statement/Prospectus titled “*Related Agreements*” beginning on page 6, which is incorporated\nherein by reference.\n\n \n\nThe foregoing\ndescription of the Merger Agreement, Transaction Documents, Certificate of Incorporation, Bylaws, and 2026 Incentive Plan do\nnot purport to be complete and is qualified in its entirety by reference to the Merger Agreement and Transaction Documents, each of which\nare attached hereto as exhibits and incorporated herein by reference.\n\n \n\n1\n\n \n\n \n\nThe following table lists the individuals who will serve as directors\nof Niki.\n\n \n\n**Name**\n \n**Position**\n\n \n \n \n\nIan Huen\n \nChairman\n\nKira Sheinerman\n \nDirector\n\nJustin Wu\n \nIndependent Director\n\nDouglas Arner\n \nIndependent Director\n\nLaura A. Philips\n \nIndependent Director\n\nAlidad Mireskandari\n \nBoard Observer"}